Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Dec;62(12):1204–1207. doi: 10.1136/ard.2002.003889

Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study

N Tsifetaki 1, G Kitsos 1, C Paschides 1, Y Alamanos 1, V Eftaxias 1, P Voulgari 1, K Psilas 1, A Drosos 1
PMCID: PMC1754388  PMID: 14644860

Abstract

Objective: To evaluate the efficacy and side effects of oral pilocarpine for the treatment of ocular symptoms in patients with primary Sjögren's syndrome (SS).

Methods: A 12 week, single centre, randomised controlled study was performed. Twenty nine patients were randomly assigned to receive oral pilocarpine (5 mg twice a day), 28 only artificial tears, and 28 inferior puncta occlusion. Patients receiving oral pilocarpine and those with inferior puncta occlusion also received artificial tears. Patients were evaluated at baseline and throughout the study for their subjective global assessment of dry eyes and for their objective assessment of dry eyes (Schirmer's-I test, rose bengal test, and imprint test).

Results: Patients taking oral pilocarpine had significant improvement in subjective global assessment of dry eyes, as was evaluated by improvement of >55 mm on a visual analogue scale (VAS) for responses to the eye questionnaire, compared with patients treated with artificial tears (p<0.001) and those with inferior puncta occlusion (p<0.05). Furthermore, patients receiving oral pilocarpine also showed greater objective improvement, as measured by the rose bengal test (p<0.05), while Schirmer's-I test showed no differences between the treated groups. Commonly reported adverse events were headache, increased sweating, nausea, and vomiting in the pilocarpine group, while one patient in the inferior puncta occlusion group had blepharitis and was withdrawn from the study.

Conclusion: 10 mg of pilocarpine daily given to patients with SS for 12 weeks had a beneficial effect on subjective eye symptoms, as evaluated by improvement >55 mm on a VAS. Additionally, an improvement of rose bengal staining was noted, but an increase in tear production, as measured by the Schirmer-I test, was not substantiated.

Full Text

The Full Text of this article is available as a PDF (244.6 KB).

Figure 1 .

Figure 1

Open in a new tab

Flow of patients and trial profile.

Figure 2 .

Figure 2

Open in a new tab

Subjective improvement of occular symptoms in patients with primary SS.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balaram M., Schaumberg D. A., Dana M. R. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol. 2001 Jan;131(1):30–36. doi: 10.1016/s0002-9394(00)00620-6. [DOI] [PubMed] [Google Scholar]
  2. Bell M., Askari A., Bookman A., Frydrych S., Lamont J., McComb J., Muscoplat C., Slomovic A. Sjögren's syndrome: a critical review of clinical management. J Rheumatol. 1999 Sep;26(9):2051–2061. [PubMed] [Google Scholar]
  3. Drosos A. A., Skopouli F. N., Costopoulos J. S., Papadimitriou C. S., Moutsopoulos H. M. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann Rheum Dis. 1986 Sep;45(9):732–735. doi: 10.1136/ard.45.9.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fox P. C., Mandel I. D. Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol. 1992 Sep;74(3):315–318. doi: 10.1016/0030-4220(92)90066-y. [DOI] [PubMed] [Google Scholar]
  5. Fox R. I., Chan E., Benton L., Fong S., Friedlaender M., Howell F. V. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988 Oct 14;85(4A):62–67. doi: 10.1016/0002-9343(88)90365-8. [DOI] [PubMed] [Google Scholar]
  6. Fox R. I., Stern M., Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000 Sep;12(5):391–398. doi: 10.1097/00002281-200009000-00007. [DOI] [PubMed] [Google Scholar]
  7. Fox Robert I., Stern Michael. Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl. 2002;116:3–13. [PubMed] [Google Scholar]
  8. Hingorani M., Moodaley L., Calder V. L., Buckley R. J., Lightman S. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998 Sep;105(9):1715–1720. doi: 10.1016/S0161-6420(98)99043-1. [DOI] [PubMed] [Google Scholar]
  9. Kunert K. S., Tisdale A. S., Stern M. E., Smith J. A., Gipson I. K. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000 Nov;118(11):1489–1496. doi: 10.1001/archopht.118.11.1489. [DOI] [PubMed] [Google Scholar]
  10. Masunaga H., Ogawa H., Uematsu Y., Tomizuka T., Yasuda H., Takeshita Y. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. Eur J Pharmacol. 1997 Nov 19;339(1):1–9. doi: 10.1016/s0014-2999(97)01338-1. [DOI] [PubMed] [Google Scholar]
  11. Moutsopoulos H. M. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994 Aug;72(2):162–165. doi: 10.1006/clin.1994.1123. [DOI] [PubMed] [Google Scholar]
  12. Petrone Dianne, Condemi John J., Fife Rose, Gluck Oscar, Cohen Stanley, Dalgin Paul. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002 Mar;46(3):748–754. doi: 10.1002/art.510. [DOI] [PubMed] [Google Scholar]
  13. Price E. J., Rigby S. P., Clancy U., Venables P. J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol. 1998 May;25(5):896–899. [PubMed] [Google Scholar]
  14. Rhodus N. L. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. Oral Dis. 1997 Jun;3(2):93–98. doi: 10.1111/j.1601-0825.1997.tb00019.x. [DOI] [PubMed] [Google Scholar]
  15. Ship J. A., Fox P. C., Michalek J. E., Cummins M. J., Richards A. B. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 1999 Aug;19(8):943–951. doi: 10.1089/107999099313497. [DOI] [PubMed] [Google Scholar]
  16. Skopouli F. N., Jagiello P., Tsifetaki N., Moutsopoulos H. M. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol. 1996 Sep-Oct;14(5):555–558. [PubMed] [Google Scholar]
  17. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carsons S. E., Daniels T. E., Fox P. C., Fox R. I., Kassan S. S. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554–558. doi: 10.1136/ard.61.6.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vivino F. B., Al-Hashimi I., Khan Z., LeVeque F. G., Salisbury P. L., 3rd, Tran-Johnson T. K., Muscoplat C. C., Trivedi M., Goldlust B., Gallagher S. C. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999 Jan 25;159(2):174–181. doi: 10.1001/archinte.159.2.174. [DOI] [PubMed] [Google Scholar]
  19. Vivino F. B. The treatment of Sjögren's syndrome patients with pilocarpine-tablets. Scand J Rheumatol Suppl. 2001;115:1–13. doi: 10.1080/030097401300232583. [DOI] [PubMed] [Google Scholar]
  20. Waterman S. A., Gordon T. P., Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum. 2000 Jul;43(7):1647–1654. doi: 10.1002/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  21. Wiseman L. R., Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs. 1995 Jan;49(1):143–155. doi: 10.2165/00003495-199549010-00010. [DOI] [PubMed] [Google Scholar]
  22. de Rojas M. V., Rodriguez M. T., Ces Blanco J. A., Salorio M. S. Impression cytology in patients with keratoconjunctivitis sicca. Cytopathology. 1993;4(6):347–355. doi: 10.1111/j.1365-2303.1993.tb00113.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES